Videos

  Clinical Conversations by Experts View all

Featured Videos

Advanced Bladder Cancer

Beyond Androgen Blockade - Exploring New Pathways for Treating mCRPC and mHSPC

APCCC 2024

Latest Videos

EMBARK

Recent Physician-Scientist Review Articles

  State of the Evidence Review Articles
Advanced Bladder Cancer
View all Advanced Bladder Cancer
PSMA-Targeted Therapy
View all PSMA-Targeted Therapy

Transformative Evidence

  Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information

ANKTIVA

Presented by Sandeep Reddy, MD
The 2025 GU ASCO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Sandeep Reddy discussing ResQ132A, a phase 2 trial of intravesical gemcitabine + N-803 versus intravesical N-803 and BCG for intermediate-risk non-muscle invasive papillary bladder cancer (NMIBC).

ARANOTE

Presented by Fred Saad, MD, FRCS
 The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Fred Saad discussing a subgroup analysis of the phase 3 ARANOTE trial assessing darolutamide + ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume. Darolutamide + ADT significantly reduced the risk of radiological progression or death by 46% (HR 0.54, 95% CI 0.41–0.71; p < 0.0001) versus placebo plus ADT in patients with mHSPC in the ARANOTE trial.

Trials in Progress

  Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information

CORE-008 Trial

Presented by Trinity Bivalacqua, MD
The 2025 GU ASCO annual meeting featured a urothelial carcinoma trials in progress session and a presentation by Dr. Trinity Bivalacqua discussing CORE-008, a phase 2, multi-arm, multi-cohort, open-label study to evaluate intravesical cretostimogene grenadenorepvec in participants with high-risk non-muscle invasive bladder cancer.

CLARIFY Trial

Presented by Michael A. Gorin, MD
 The 2025 GU ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Michael Gorin discussing CLARIFY, a phase 3 diagnostic performance study assessing PET using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy. Prostate cancer is the second most prevalent cancer in men globally. In men with newly diagnosed, high-risk disease, prostate cancer most often spreads to the pelvic lymph nodes before becoming widely metastatic.